BioCentury
ARTICLE | Clinical News

Baricitinib: Additional Phase III data

July 20, 2015 7:00 AM UTC

Additional data from the double-blind, international Phase III RA-BUILD trial in 684 patients with moderately to severely active RA who had an inadequate response to, or were intolerant of, >=1 conven...